Perspective on measurable residual disease testing in acute myeloid leukemia

Roland B Walter^{1

2

3}

Affiliations

¹ Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. rwalter@fredhutch.org.
² Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA, USA. rwalter@fredhutch.org.
³ Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA. rwalter@fredhutch.org.

Review

Roland B Walter. Leukemia. 2024 Jan.

. 2024 Jan;38(1):10-13.

doi: 10.1038/s41375-023-02084-8. Epub 2023 Nov 16.

Roland B Walter^{1

2

3}

¹ Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. rwalter@fredhutch.org.
² Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA, USA. rwalter@fredhutch.org.
³ Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA. rwalter@fredhutch.org.

No abstract available

References

1. Hourigan CS, Gale RP, Gormley NJ, Ossenkoppele GJ, Walter RB. Measurable residual disease testing in acute myeloid leukaemia. Leukemia. 2017;31:1482–90. - DOI - PubMed
1. Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138:2753–67. - DOI - PubMed - PMC
1. Robinson TM, Bowman RL, Persaud S, Liu Y, Neigenfind R, Gao Q, et al. Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia. Sci Adv. 2023;9:eadg0488. - DOI - PubMed - PMC
1. Tettero JM, Freeman S, Buecklein V, Venditti A, Maurillo L, Kern W, et al. Technical aspects of flow cytometry-based measurable residual disease quantification in acute myeloid leukemia: experience of the European LeukemiaNet MRD Working Party. Hemasphere. 2022;6:e676. - DOI - PubMed
1. Canali A, Vergnolle I, Bertoli S, Largeaud L, Nicolau ML, Rieu JB, et al. Prognostic impact of unsupervised early assessment of bulk and leukemic stem cell measurable residual disease in acute myeloid leukemia. Clin Cancer Res. 2023;29:134–42. - DOI - PubMed